See past issues in our Newsletter Archives
In this issue:
-
- WHO SAGE reviews typhoid vaccine policy, highlighting potential updates to TCV use
- Momentum builds for typhoid prevention in 2026
- Global experts gather at the 14th International Conference on Typhoid & Other Invasive Salmonelloses
- New cost data from Burkina Faso informs vaccine delivery at scale
- New global analysis confirms high typhoid burden
- Dr. Senjuti Saha recognized with Rising Star Award
- Outbreak report
- Stay engaged
- link
- Scientific publications
- Blogs
WHO SAGE reviews typhoid vaccine policy, highlighting potential updates to TCV use
In March 2026, the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization reviewed the latest evidence on typhoid conjugate vaccines (TCV), including data on duration of protection and vaccination strategies.
Based on this review, SAGE emphasized the continued importance of introducing TCV in high-burden settings and discussed considerations for optimizing use, including the potential role of booster doses in populations at highest risk. These deliberations will inform future WHO policy updates and revisions to global guidance on TCV use.
Updated global guidance is evolving, and countries can begin considering how emerging evidence—particularly on duration of protection—may shape future vaccine strategies.
Momentum builds for typhoid prevention in 2026
From evolving global vaccine guidance to emerging evidence on cost, burden, and real-world impact, recent developments underscore growing global momentum and opportunity to accelerate progress against typhoid.
Global experts gather at the 14th International Conference on Typhoid & Other Invasive Salmonelloses
More than 250 researchers, policymakers, and health experts convened in March 2026 at the 14th International Conference on Typhoid & Other Invasive Salmonelloses, hosted by Sabin Vaccine Institute in Phnom Penh, Cambodia.
Discussions spanned:
-
- Antimicrobial resistance trends
- Advances in disease surveillance
- TCV introduction and real-world impact
- Strategies to improve equitable access
The conference theme—Innovation and Equity: Shaping the Future of Typhoid and Other Invasive Salmonelloses—highlighted the need to translate scientific advances into measurable gains for high-burden communities. “We have an effective vaccine against typhoid, and we have a growing set of complementary tools,” wrote Sabin Vice President of Vaccine Epidemiology Denise Garrett ahead of the conference. “The work now is to connect innovation with measurable, equitable impact for the communities that have carried the burden of typhoid and other invasive salmonellosis for far too long.”
Progress against typhoid will depend on integrating vaccines, surveillance, and innovation to reach the communities most affected.
New cost data from Burkina Faso informs vaccine delivery at scale
A new analysis of Burkina Faso’s 2025 nationwide TCV campaign provides detailed insights into the cost of delivering vaccines at scale. Conducted by PATH in collaboration with the Burkina Faso Ministry of Health and Davycas International, the study examines both financial and economic costs across all levels of the health system.
The findings identify key cost drivers, particularly human resources and service delivery, and show how costs vary by geography, delivery strategy, and security context. This type of context-specific evidence is critical for planning future vaccination campaigns, and informs decision-making for TCV introductions across similar settings. Read the full manuscript here: Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso.
Practical cost data helps countries design smarter, more efficient TCV introduction strategies.
New global analysis confirms high typhoid burden
An updated systematic review and meta-analysis led by researchers at the University of Otago reaffirms that typhoid remains a significant public health challenge, particularly in Asia and Africa.
Drawing on 46 studies (including 14 new datasets), the analysis finds:
- Persistently high incidence in multiple regions
- The highest burden among young children aged 2 to <5 years
These findings reinforce earlier estimates while adding new geographic and age-specific insights.
Read the full article here: Global typhoid fever incidence: an updated systematic review with meta-analysis – The Lancet Infectious Diseases.
The sustained burden of disease underscores the urgency of expanding TCV use alongside improvements in water and sanitation.
Dr. Senjuti Saha recognized with Rising Star Award
The Sabin Vaccine Institute awarded its 2026 Rising Star Award to Dr. Senjuti Saha of Bangladesh for her pioneering work using genomics to inform public health action.
As Deputy Executive Director of the Child Health Research Foundation (CHRF), Dr. Saha helped build one of Bangladesh’s leading genomic research programs. Her work has contributed to major national immunization initiatives, including the country’s 2025 TCV introduction campaign, which reached more than 40 million children.
Learn more here.
Scientific leadership and local research capacity are critical to advancing evidence-based immunization programs.
Outbreak report
Stay engaged
As new evidence and policy guidance continue to emerge, staying informed—and sharing knowledge—remains essential to accelerating progress against typhoid.
Explore more resources: www.takeontyphoid.org
Share this newsletter with colleagues working in immunization and global health.
